RT @JohnEbbenMDPhD
Awesome #TumorBoardTuesday this week- excited to see how potential approval (soon?) of enfortumab + pembrolizumab will influence 1L approaches in #metastaticurothelialcarcinoma. Thank you @drfrankiejs & @tompowles1! https://twitter.com/TumorBoardTues/status/1641957605764653056

Awesome #TumorBoardTuesday this week- excited to see how potential approval (soon?) of enfortumab + pembrolizumab will influence 1L approaches in #metastaticurothelialcarcinoma. Thank you @drfrankiejs & @tompowles1!
---
RT @TumorBoardTues
3/5 #TumorBoardTuesday
🎥 TBT in a video

Tx of #urothelialcarcinoma is changing- some ❓re: adj IO after resection.

🧐 Will ctDNA define pt population for whom adj IO is most likely to ➡️benefit? Ch…
https://twitter.com/TumorBoardTues/status/1641957605764653056